Methods
A retrospective review of medical records of patients with primary CNS or peripheral nervous system (PNS) malignancies treated at Children’s Hospital Colorado to identify children treated with MEK inhibitors and lenalidomide concurrently.
Results We identified four pediatric patients with primary CNS or PNS tumors treated with concurrent trametinib (0.032 mg/kg/day for patients less than 6 years old; 0.025 mg/kg/day for patients 6 years and older) and lenalidomide (25 mg/m2/day on days 1-21 of each 28-day cycle).